You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

~ Buy the DUEXIS (famotidine; ibuprofen) Drug Profile, 2024 PDF Report in the Report Store ~

DUEXIS Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Duexis, and when can generic versions of Duexis launch?

Duexis is a drug marketed by Horizon and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has twenty-five patent family members in fifteen countries.

The generic ingredient in DUEXIS is famotidine; ibuprofen. There are eighteen drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the famotidine; ibuprofen profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Duexis

A generic version of DUEXIS was approved as famotidine; ibuprofen by ENDO OPERATIONS on March 22nd, 2024.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for DUEXIS?
  • What are the global sales for DUEXIS?
  • What is Average Wholesale Price for DUEXIS?
Drug patent expirations by year for DUEXIS
Drug Prices for DUEXIS

See drug prices for DUEXIS

Drug Sales Revenue Trends for DUEXIS

See drug sales revenues for DUEXIS

Recent Clinical Trials for DUEXIS

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Horizon Pharma Ireland, Ltd., Dublin IrelandPhase 4
Pediatric Rheumatology Collaborative Study GroupPhase 4

See all DUEXIS clinical trials

Paragraph IV (Patent) Challenges for DUEXIS
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
DUEXIS Tablets famotidine; ibuprofen 800 mg/26.6 mg 022519 1 2011-12-06

US Patents and Regulatory Information for DUEXIS

DUEXIS is protected by five US patents.

Patents protecting DUEXIS

Methods and medicaments for administration of ibuprofen
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: RELIEF OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS AND TO DECREASE RISK OF DEVELOPING UPPER GASTROINTESTINAL ULCERS IN PATIENTS WHO ARE TAKING IBUPROFEN FOR THOSE INDICATIONS

Stable compositions of famotidine and ibuprofen
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Stable compositions of famotidine and ibuprofen
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Stable compositions of famotidine and ibuprofen
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Stable compositions of famotidine and ibuprofen
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: RELIEF OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS AND TO DECREASE RISK OF DEVELOPING UPPER GASTROINTESTINAL ULCERS IN PATIENTS WHO ARE TAKING IBUPROFEN FOR THOSE INDICATIONS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Horizon DUEXIS famotidine; ibuprofen TABLET;ORAL 022519-001 Apr 23, 2011 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Horizon DUEXIS famotidine; ibuprofen TABLET;ORAL 022519-001 Apr 23, 2011 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Horizon DUEXIS famotidine; ibuprofen TABLET;ORAL 022519-001 Apr 23, 2011 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Horizon DUEXIS famotidine; ibuprofen TABLET;ORAL 022519-001 Apr 23, 2011 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Horizon DUEXIS famotidine; ibuprofen TABLET;ORAL 022519-001 Apr 23, 2011 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for DUEXIS

When does loss-of-exclusivity occur for DUEXIS?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 06269894
Patent: Medicaments containing famotidine and ibuprofen and administration of same
Estimated Expiration: ⤷  Sign Up

Patent: 07275360
Patent: Methods and medicaments for administration of ibuprofen
Estimated Expiration: ⤷  Sign Up

Austria

Patent: 39747
Estimated Expiration: ⤷  Sign Up

Brazil

Patent: 0714937
Patent: forma de dosagem unitÁria oral, e, uso de uma forma de dosagem unitÁria
Estimated Expiration: ⤷  Sign Up

Canada

Patent: 15496
Patent: MEDICAMENTS CONTENANT FAMOTIDINE ET IBUPROFENE, ET ADMINISTRATION DESDITS MEDICAMENTS (MEDICAMENTS CONTAINING FAMOTIDINE AND IBUPROFEN AND ADMINISTRATION OF SAME)
Estimated Expiration: ⤷  Sign Up

Patent: 57928
Patent: PROCEDES ET MEDICAMENTS DESTINES A L'ADMINISTRATION D'IBUPROFENE (METHODS AND MEDICAMENTS FOR ADMINISTRATION OF IBUPROFEN)
Estimated Expiration: ⤷  Sign Up

China

Patent: 1257800
Patent: Medicaments containing famotidine and ibuprofen and administration of same
Estimated Expiration: ⤷  Sign Up

Patent: 1516368
Patent: Methods and medicaments for administration of ibuprofen
Estimated Expiration: ⤷  Sign Up

Denmark

Patent: 43637
Estimated Expiration: ⤷  Sign Up

European Patent Office

Patent: 19288
Patent: MEDICAMENTS CONTENANT FAMOTIDINE ET IBUPROFENE, ET ADMINISTRATION DESDITS MEDICAMENTS (MEDICAMENTS CONTAINING FAMOTIDINE AND IBUPROFEN AND ADMINISTRATION OF SAME)
Estimated Expiration: ⤷  Sign Up

Patent: 43637
Patent: PROCÉDÉS ET MÉDICAMENTS DESTINÉS À L'ADMINISTRATION D'IBUPROFÈNE (METHODS AND MEDICAMENTS FOR ADMINISTRATION OF IBUPROFEN)
Estimated Expiration: ⤷  Sign Up

Patent: 38919
Patent: Compositions contenant de l'ibuprofene et de la famotidine ainsi que des compositions contenant de 25 mg a 28 mg de la famotidine (Compositions comprising famotidine and ibuprofen as well as compositions comprising 25 mg to 28 mg famotidine)
Estimated Expiration: ⤷  Sign Up

Israel

Patent: 8732
Patent: שימוש באיבופרופין ופאמוטידין להכנת תרופות (Use of ibuprofen and famotidine in the preparation of medicaments)
Estimated Expiration: ⤷  Sign Up

Patent: 6425
Patent: יחידת מינון למתן פומי המכילה איבופרופן ופאמוטידין (Oral unit dose form containing ibuprofen and famotidine)
Estimated Expiration: ⤷  Sign Up

Japan

Patent: 09501801
Estimated Expiration: ⤷  Sign Up

Patent: 09543885
Estimated Expiration: ⤷  Sign Up

New Zealand

Patent: 5846
Patent: Medicaments containing famotidine and ibuprofen and administration of same
Estimated Expiration: ⤷  Sign Up

Patent: 4200
Patent: METHODS AND MEDICAMENTS FOR ADMINISTRATION OF IBUPROFEN AND FAMOTIDINE
Estimated Expiration: ⤷  Sign Up

Poland

Patent: 43637
Estimated Expiration: ⤷  Sign Up

Portugal

Patent: 43637
Estimated Expiration: ⤷  Sign Up

South Africa

Patent: 0900423
Patent: Methods and medicaments for administration of ibuprofen
Estimated Expiration: ⤷  Sign Up

Spain

Patent: 80747
Estimated Expiration: ⤷  Sign Up

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering DUEXIS around the world.

Country Patent Number Title Estimated Expiration
Denmark 2043637 ⤷  Sign Up
World Intellectual Property Organization (WIPO) 2007012022 ⤷  Sign Up
South Africa 200900423 Methods and medicaments for administration of ibuprofen ⤷  Sign Up
Israel 188732 שימוש באיבופרופין ופאמוטידין להכנת תרופות (Use of ibuprofen and famotidine in the preparation of medicaments) ⤷  Sign Up
Japan 2009543885 ⤷  Sign Up
Poland 2043637 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.